Light-triggered release of lenalidomide with fluorescent indication for inhibition of COX-2 enzyme activity in cancer cells

Abstract

In this work, we have developed a Sanger's reagent-based photocage, LNDA-NBD-Sanger, which releases the caged COX-2 inhibitor, lenalidomide (LNDA), under 400 nm UV irradiation while producing a fluorescent signal from the activated nitrobenzoxadiazole (NBD) derivative, realizing the monitoring of LNDA release in cancer cells and light-controlled anti-cancer therapy.